Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents

      

This page is updated frequently with new Mammal-related patent applications.




Date/App# patent app List of recent Mammal-related patents
08/18/16
20160238587 
 Method for testing a biological sample in doping and/or drug tests patent thumbnailMethod for testing a biological sample in doping and/or drug tests
The present teachings describe a method for testing a biological sample, including (a) obtaining a biological sample from a mammal, (b) acquiring at least two extracellular endogenous metabolic products from the biological sample, (c) detecting the at least two extracellular endogenous metabolic products from the extract, (d) determining a pattern on the basis of the presence or the mass ratio of the at least two extracellular endogenous metabolic products, (e) comparing the pattern with the pattern from a retention sample.. .

08/18/16
20160237390 
 Tissue extracellular matrix particles and applications patent thumbnailTissue extracellular matrix particles and applications
An apparatus in the form of a chip is provided wherein the apparatus is prepared with decellularized extracellular matrix from various tissues and can be used to investigate the cellular interactions between the ecm and the various cell types. Three dimensional culture methods for investigating decellularized extracellular matrix from various tissues and interactions with various mammalian cell types are also provided.
The Johns Hopkins University


08/18/16
20160237141 
 Methods of treating alzheimer's disease with apo a-1 milano patent thumbnailMethods of treating alzheimer's disease with apo a-1 milano
This invention relates to the treatment of alzheimer's disease, the reduction of the progression of alzheimer's disease, and the alleviation of symptoms of alzheimer's disease by administering apoa-1 milano based therapies to provide anti-inflammatory, antioxidant, and lipid depleting effects to brain tissue. In particular embodiments, the method comprises administering a composition comprising an raav vector encoding apoa-1 milano or an active fragment thereof, to a mammal having alzheimer's disease or a symptom of alzheimer's disease..
Cedars-sinai Medical Center


08/18/16
20160237052 
 Histamine-3 receptor antagonists patent thumbnailHistamine-3 receptor antagonists
The invention is directed to a compound of formula i, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula i; and a method of treatment of a disorder or condition selected from the list consisting of acute myocardial infarction; memory processes disorders; dementia; cognition disorders such as alzheimer's disease; attention deficit disorder (add); attention-deficit hyperactivity disorder (adhd); cancers such as cutaneous carcinoma, medullary thyroid carcinoma and melanoma; meniere's disease; gastrointestinal disorders; inflammation; migraine; motion sickness; obesity; pain; septic shock; respiratory disorders (including allergic rhinitis, nasal congestion and allergic congestion) in a mammal, including a human, that may be effected by administering to said mammal a pharmacologically effective amount of a compound of formula i, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.. .
Medisynergics, Llc


08/18/16
20160235982 
 Non-invasive selective human and mammalian nerve stimulation system and method patent thumbnailNon-invasive selective human and mammalian nerve stimulation system and method
What is provided is an apparatus, system and method for selectively activating one or more target nerves of a mammal by an electric field, including a wireless topical nerve stimulation dermal patch having one or more electrodes configured to provide electric stimulation to one or more target nerves, and a controller configured to receive one or more user inputs and wireless communication from the topical nerve stimulation dermal patch, and configured to send one or more control requests to the topical nerve stimulation dermal patch. The controller configured to determine an activation pattern for the electrodes of the dermal patch to selectively apply the electric field to the target nerve by shaping the electric field in a volume of tissue in proximity of the target nerve by the activation pattern of the electrodes, and the dermal patch configured to activate the electrodes in accordance with the specified activation pattern..
Neurostim Solutions Llc


08/18/16
20160235787 
 Epitope spreading associated with car t-cells patent thumbnailEpitope spreading associated with car t-cells
The present invention relates to compositions and methods for inducing epitope spreading by administering to a mammal an effective amount of a cell genetically modified to express a chimeric antigen receptor (car). The invention also relates to identification of antigens and antibodies involved in the epitope spreading associated with car t cells..
The Trustees Of The University Of Pennsylvania


08/18/16
20160235759 
 Kappa opioid receptor compounds patent thumbnailKappa opioid receptor compounds
The invention is directed to a method of treatment for chronic pain, the method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula i, or a pharmaceutically acceptable salt thereof.. .
Medisynergics, Llc


08/18/16
20160235721 
 Benzoheterocyclic compounds and use thereof patent thumbnailBenzoheterocyclic compounds and use thereof
Disclosed are compound of formula (i) and pharmaceutically accepted salts and prodrugs thereof, wherein each of r1, r2, r3, r4, r5, r6, x1, and x2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of mek, which are useful in the treatment of cancers and inflammation of mammals.
Shanghai Kechow Pharma Inc.


08/18/16
20160235712 
 Cancer treatment method patent thumbnailCancer treatment method
Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (tpo) receptor agonist to such mammal, suitably a human.. .
Novartis Ag


08/18/16
20160235693 
 Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level patent thumbnailCompositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders.
Pharnext


08/18/16
20160235574 

Lumbar support device


Provided are adjustable, modular lumbar support devices that may be used to provide lumbar and/or belly support for mammals having belly weight. According to non-limiting example embodiments, support or brace devices provided herein may be worn by pregnant women at various stages throughout a woman's pregnancy, and/or post-partum and may be adjusted to naturally contour/conform to the woman's anatomy, which changes throughout pregnancy.

08/11/16
20160231332 

Methods and devices for detecting kidney damage


Methods and devices for diagnosing, monitoring, or determining kidney damage in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney damage using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described..
Rules-based Medicine, Inc.


08/11/16
20160230155 

Modified sulfamidase and production thereof


Disclosed herein are a modified sulfamidase, a composition comprising a modified sulfamidase, as well as methods for preparing a modified sulfamidase and therapeutic use of such a sulfamidase. In particular, the present disclosure relates to a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal..
Swedish Orphan Biovitrum Ab (publ)


08/11/16
20160229897 

Hepatitis b virus vaccines


This document provides methods and materials for producing immune responses against hepatitis b viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis b viruses within mammals (e.g., humans) are provided..
Altravax, Inc.


08/11/16
20160229888 

N-substituted indenoisoquinolines and syntheses thereof


N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
Purdue Research Foundation


08/11/16
20160229865 

Compound inhibiting activities of btk and/or jak3 kinases


The present invention relates to a compound inhibiting the activities of bruton's tyrosine kinase (btk) and/or janus kinase 3 (jak3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of btk and/or jak3, and a method for using the compound in treatment and/or prevention of btk- and/or jak3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (i)..
Beijing Hanmi Pharmaceutical Co., Ltd.


08/11/16
20160229851 

New 3-(1h-pyrazol-4-yl)-1h-pyrrolo[2,3-c]pyridine derivatives as nik inhibitors


The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv


08/11/16
20160229846 

Composition and methods for the treatment of camkk2-mediated disorders


The present disclosure provides compositions and methods for treating ocular disorders in mammals especially in and not limited to humans and mice. The present disclosure further provides methods of treating cancer and appetite suppression using the compositions which are novel small molecule inhibitors of camkk2.
Duke University


08/11/16
20160229823 

Deuterated compounds useful for treating neurodegenerative diseases


The present application is related to deuterated compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders involving degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such deuterated compounds..
Pharmatrophix, Inc.


08/11/16
20160228563 

Lipidated peptides for lowering blood glucose


Lipidated analogs of prolactin-releasing peptides (prrp) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of prrp20 and prrp31.
Fyziologicky Ustav Akademie Ved Cr, V.v.i.


08/11/16
20160228523 

Compositions and methods for treatment of cancer using bacteria


Provided herein are compositions comprising substantially non-viable gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer.
Decoy Biosystems, Inc.


08/11/16
20160228488 

Novel inhibitors of mammalian tight junction opening


The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. Peptide tight junction antagonists.
Alba Therapeutics Corporation


08/11/16
20160228487 

Methods and compositions for the prevention or treatment of barth syndrome


The disclosure provides methods of preventing or treating barth syndrome in a mammalian subject, reducing risk factors associated with barth syndrome, and/or reducing the likelihood or severity of barth syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of taz1 in subjects in need thereof..
Stealth Biotherapeutics Corp.


08/11/16
20160228441 

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds


Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or typanosoma cruzi infection in a mammal.. .
Array Biopharma, Inc.


08/11/16
20160228432 

Heteroaryl pyridone and aza-pyrodine compounds


Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating immune disorders such as inflammation mediated by btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
Genentech, Inc.


08/11/16
20160228426 

Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients


Described herein are methods of treating a mammal in need of treatment for non-histaminic pruritus by administering to the mammal in need thereof a therapeutically effective amount of rs-norketotifen or a pharmaceutically acceptable salt thereof, thereby reducing the desire to scratch in the mammal. Non-histaminergic types of pruritus are resistant to treatment with selective histamine h-1-, h-2- and h-4-receptor inhibitors.
Bridge Pharma, Inc.


08/11/16
20160228387 

Solubilized formulation of coq10 for use in treatment of parkinson's disease


Provided herein are compositions and methods for reducing neurogeneration in a patient suffering from parkinson's disease, comprising administration of a composition comprising coq10 and polyoxyethanyl-a-tocopherylsebacate (pts). The compositions of the invention have been shown to penetrate the blood-brain barrier in mammals, thus effecting delivery of coq10 directly to brain tissue.
University Of Windsor


08/11/16
20160228384 

Emulsion containing two oils and stabilizers


The present invention relates to improved formulations for administration lipophilic drugs, and in particular to improved propofol formulations. Emulsion of the present invention preferably comprise oil droplets of a mean oil particle diameter of 80-300 nanometers; and a continuous aqueous phase comprising a lipophilic drug in an amount 0.5-5.0% by weight relative to the weight of the total emulsion, wherein said lipophilic drug has a solubility in water of less than 1 mg/ml; a primary oil physiologically suitable for parenteral administration to a mammal comprising plant-derived biocompatible long chain triglycerides; and a secondary oil comprising an ethyl ester of a saturated, unbranched carboxylic acid of 4-8 carbon atoms or an unbranched alkyl esters of acetic acid, said alkyl residue having 4-8 carbon atoms, or combination thereof, the combined percentage by weight of the oil components not exceeding about 10 percent..
Nanomedex, Llc


08/11/16
20160228339 

Oral hygiene compositions


Mouth hygiene compositions that reduce vsc by changing the growth conditions in the oral cavity in favor of bacteria capable of anaerobic respiration. Anaerobic respiration is a form of respiration that involves electron acceptors other than oxygen.
Glymur B.v.


08/11/16
20160228085 

A estimating perfusion indices


The present invention relates to a method for estimating perfusion indices (pi) in a mammal (200), e.g. A human.
Aarhus Universitet


08/04/16
20160222356 

High titer recombinant aav vector production in adherent and suspension cells


Disclosed are an in vitro method of producing a recombinant aav virion in a mammalian host cell that comprises a functional adenoviral e1a gene (e.g., a hek 293 cell) and raav virions made by the method.. .
Amgen Inc.


08/04/16
20160222128 

Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis


The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of loxl2 expression and activity, such as shrna targeting loxl2..
Technion Research & Development Foundation Limited


08/04/16
20160222093 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222092 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222091 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222090 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160222088 

Recombinant clusterin and use thereof in the treatment and prevention of disease


Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism)..
Board Of Regents Of The University Of Texas System


08/04/16
20160222071 

Analogs of sodium channel peptide toxin


The present invention relates to a peptide and analogs thereof that selectively inhibit the nav1.7 sodium channel. The present invention also relates to pharmaceutical compositions useful for treating or preventing a disorder responsive to the blockade of sodium ion channels, especially nav1.7 sodium ion channels.
Purdue Pharma L.p.


08/04/16
20160222069 

Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species


The invention relates to three isolated dna molecules that encode for proteins, bigl1, bigl2 and bigl3, in the leptospira sp bacterium which have repetitive bacterial-ig-like (big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for bigl1, bigl2 and bigl3 proteins are used for the diagnosis and prevention of infection with leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance..
Fundação Oswaldo Cruz - Fiocruz


08/04/16
20160222013 

Novel benzodiazepine derivatives


The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (i) and (ii), in which the diazepine ring (b) is fused with a heterocyclic ring (cd), wherein the heterocyclic ring is bicyclic or a compound of formula (iii), in which the diazepine ring (b) is fused with a heterocyclic ring (c), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds.
Immunogen, Inc.


08/04/16
20160221427 

Pest protection


Disclosed is a pliable bag comprised of a mammal pest barrier resistant to mammal pest passage therethrough. The bag is sized and shaped to receive a ground vehicle, such as an automobile, a truck, a recreational vehicle, farming equipment, construction equipment or the like.

08/04/16
20160220813 

Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function


In one example embodiment, a neuromodulation system for inducing locomotor activity in a mammal, in cooperation with a signal generator and an electrode, delivers a signal with an overlapping high frequency pulse to a mammal.. .
Neuroenabling Technologies, Inc.


08/04/16
20160220701 

Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders


Recombinant cells and methods are provided that relate to the use of isolated, engineered recombinant cells to directly or indirectly treat diseases or disorders in a mammalian host such as endocrine, gastrointestinal or autoimmune disorders. A recombinant cell is provided that comprises a signal sequence and a promoter, wherein: the signal sequence is capable of regulating signal-dependent expression of a target nucleic acid in a host or is capable of regulating signal-dependent expression of a target nucleic acid in response to an environmental stimulus, the cell is derived from an enteric or a commensal bacterium, and the target nucleic acid encodes a mammalian factor that promotes normal functioning of a physiological process in the host or is effective in preventing onset, establishment, or spread of a non-infectious disease in the host.
Cornell University


08/04/16
20160220662 

Immunogenic formulation containing recombinant live bcg that express antigens of metapneumovirus (hmpv), in a suspension prepared from a lyophilisate, without requiring an adjuvant, suitable for pharmaceutical use


The present invention relates to an immunogenic formulation to be used in mammals against human metapneumovirus (hmpv), consisting of a lyophilisate of 1×109 ufc/ml of recombinant bcg that expresses the viral protein p of hmpv (of genogroups a1, a2, b1 and b2). The vaccine is derived from the full or partial product of the p gene of hmpv, capable of being used, stabilised and administered in solution without requiring adjuvants.
Pontificia Universidad Catolica De Chile


08/04/16
20160220637 

Pharmaceutical compositions of growth hormone secretagogue receptor ligands


The present invention relates to improvements in compositions containing peptides that are ligands of the ghs receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of h-inp-d-bal-d-trp-phe-apc-nh2, which is a ligand of the ghs receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological ph that is slowly dissolved and released into the body fluid and bloodstream.
Ipsen Pharma S.a.s.


08/04/16
20160220618 

Methods for collecting and using placenta cord blood stem cells


An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device.
Anthrogenesis Corporation


08/04/16
20160220609 

Regulation of steroidogenic activity by using purified shilajit


A method of using purified shilajit to promote steroidogenic activity in a mammal is provided.. .
Natreon, Inc.


08/04/16
20160220578 

Combination therapy for tuberculosis


The present invention relates to methods of treating tuberculosis, including multi-drug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (i), (s)—n-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or a pharmaceutically acceptable salt thereof in combination with at least two agents useful in the treatment of tuberculosis.
The Johns Hopkins University


08/04/16
20160220526 

Method of treating or preventing tumors using 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene


A method of treating or preventing human or mammalian cancer and tumor including administering to a patient or an animal in need thereof a pharmaceutical composition, a health product, or a food additive, including 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene.. .
Beijing University Of Chemical Technology


08/04/16
20160220467 

Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives


A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin.
Duke University


08/04/16
20160219880 

Peptoid oligomers, pharmaceutical compositions and methods of using the same


The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics..

08/04/16
20160219859 

Organism control device and method


Pest control in an enclosed area, such as a room of a building, by positioning an ozone producing device in an area to be treated. Ozone generating ultraviolet lamps emit ozone around the entire perimeter of the device, generating ozone from the atmosphere within the enclosed area.
Uvas, Llc


08/04/16
20160219850 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160219849 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160219848 

Non-human mammals for the production of chimeric antibodies


The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits.
Ablexis, Llc


08/04/16
20160219846 

Animal models and therapeutic molecules


The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited


08/04/16
20160219844 

T cell receptors that are specific to a fluorescent protein, transgenic animals and methods of their making, isolated t cells, and methods of use


This invention relates to a transgenic non-human mammal whose genome comprises a polynucleotide sequence encoding a t cell receptor that is specific to a fluorescent protein, where the t cell of the non-human mammal comprises the t cell receptor. The present invention also relates to an isolated t cell from the transgenic non-human mammal of the present invention, an isolated t cell comprising an expression construct comprising a polynucleotide sequence that encodes a t cell receptor that is specific to a fluorescent protein, methods of making transgenic non-human mammals comprising t cell receptors that are specific to a fluorescent protein, a method of depleting cells in a non-human mammal using isolated t cells that encode a t cell receptor that is specific to a target protein, and a method of characterizing a t cell response to an agent..
Icahn School Of Medicine At Mount Sinai


08/04/16
20160219833 

Animal grooming device


An animal grooming assembly includes a housing structured to resemble an animal. The housing is further structured to have a front section removably coupled to a rear section to access an interior of the housing.

07/28/16
20160215319 

Improved process for production of monoclonal antibodies


The present invention provides for an improved process to obtain substantial amount of monoclonal antibodies with desired profile of charged variants. The process involves initially culturing e mammalian cells at a suitable temperature and subsequently reducing the temperature and optionally by simultaneous addition of suitable amino acid(s) during production of the desired molecule.
Cadila Helthcare Limited


07/28/16
20160215297 

Mammalian gene modification method using electroporation


An object is to develop a technology enabling utilization, by only an extremely simple technique, of a technology which is widely applicable to mammals without requiring the utilization of an es cell, and which involves modifying a certain gene by targeting a certain sequence on a genome (genome editing technology based on zfn or the like). Provided is a technology for efficiently modifying an arbitrary target gene of a mammal, by immersing a pronuclear stage mammalian zygote with an intact zona pellucida into a solution containing a pair of molecules of mrna having a certain sequence, and performing electroporation treatment through application of multiple square-wave pulses in three steps with the total electric energy of a first electric pulse adjusted within a predetermined range..
Nepa Gene Co., Ltd.


07/28/16
20160215286 

Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21


This invention provides compositions and methods for preventing or treating a malignant tumor in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising rnai molecules, which rnai molecules can be active in reducing expression of hsp47, or a combination of rnai molecules active for hsp47 and p21.. .
Nitto Denko Corporation


07/28/16
20160215284 

Compositions and methods for treating lung disease and injury


Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ards), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (copd), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (pgd) after organ transplantation, in particular in lung transplantation, comprising down-regulating the tlr2 gene or both the tlr2 gene and tlr4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury..
Washington University


07/28/16
20160215267 

Methods for generating 3d cell culture model in high respiration environments for high-content analyses and screening


A method of culturing cells to form cell aggregations and subjecting the cell aggregations to imaging analysis, comprises: seeding cells in a culture medium on a substantially flat substrate that is transparent, oxygen gas-permeable and liquid impermeable and is coated with atelo-collagen of large-mammalian origin; culturing the cells by continuously supplying air or oxygen-containing gas to the cells through said substrate to form the cell aggregations that are three-dimensional (3d), shaped as undulated as islands or mountains and discretely arranged as islands separated by substantially cell-free gaps; subjecting the cell aggregations on said substrate to the imaging analysis by using lights passing through said substrate.. .
Kyoto University


07/28/16
20160215265 

Stromal stem cells


Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for sdc2..
Orbsen Therapeutics Limited


07/28/16
20160215258 

Method for preparing pluripotent stem cells


An object of the present invention is to provide a method capable of inexpensively and conveniently preparing cells having pluripotency and a very low risk of tumorigenic transformation. The cells having pluripotency and a very low risk of tumorigenic transformation can be prepared by suspension-culturing mammalian mesenchymal stem cells such as human mesenchymal stem cells from bone marrow (hmsc-bm) and human adipose tissue-derived mesenchymal stem cells (hat-msc) (also referred to as “human adipose-derived stem cells [hadsc]”), 7 types of human adherent mature cells (human hepatocyte cells [hhep cells], human umbilical vein endothelial cells [huvec cells], human dermal lymphatic microvascular endothelial cells [hmvec cells], human epidermal keratinocyte cells [nhek cells], human bronchial epithelial cells [nhbe cells], human melanocyte cells [nhem cells], and human smooth muscle cells [uasmc cells]), and 3 types of human adherent precursor cells (human dermal fibroblast cells [nhdf cells], human skeletal muscle myoblast cells [hsmm cells], and human osteoblast cells [nhost cells]) to form cell masses (spheroids)..
Otsuka Pharmaceutical Factory, Inc.


07/28/16
20160215031 

Method of treating disorders requiring destruction or removal of cells


The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in treatment naïve mammals, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a naïve mammal in need thereof who had not previously been treated for the condition..
Nymox Pharnaceutical Corporation


07/28/16
20160215025 

Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes


The invention provides a pseudomonas exotoxin a (pe) comprising an amino acid sequence having a substitution of one or more b-cell and/or t-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


07/28/16
20160215014 

Preparation and uses of obeticholic acid


Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

07/28/16
20160214956 

Novel soluble guanylate cyclase activators and their use


The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species..
Glaxosmithkline Intellectual Property Development Limited


07/28/16
20160213811 

Biopolymer system for tissue sealing


A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed.
Endomedix, Inc.


07/28/16
20160213807 

Solid dressing for treating wounded tissue


Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings..
Stb, Ltd.


07/28/16
20160213806 

Solid dressing for treating wounded tissue


Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 units/mg of fibrinogen component and 0.062 units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue..
Stb, Ltd.


07/28/16
20160213716 

Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof


The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. Via injection, transplantation, or implantation) into a site of non-soft tissue (e.g.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


07/28/16
20160213666 

Novel compound useful for the treatement of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

07/28/16
20160213664 

Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors


Provided are methods of treating a cerebral cavernous malformation (ccm) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.. .
Bioaxone Biosciences, Inc.


07/28/16
20160213652 

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use


Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of formula i, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein r2 is a cyclic ether and x is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting pim kinase, and for treating disorders such as cancer mediated by pim kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
Genentech, Inc.


07/21/16
20160208309 

In vitro estimating in vivo protein digestibility


An analysis technique can be performed to quantify the digestible protein content of a protein-containing sample outside the body of a living organism. Traditionally, protein digestibility is evaluated in vivo, for example using a rat subject to measure protein digestibility after being fed the protein-containing sample.
General Mills, Inc.


07/21/16
20160208286 

Alphaviral vectors and cell lines for producing recombinant proteins


The present invention relates to polynucleotides and alphaviral vectors for the expression of genes of interest in mammalian cells. Additionally, the invention relates to cells which comprise said polynucleotides and alphaviral vectors and are capable of stably expressing one or more genes of interest.
3p Biopharmaceuticals, S.l.


07/21/16
20160208261 

Methods and compositions for inhibiting the function of polynucleotide sequences


A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded rna molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This rna molecule desirably does not produce a functional protein.
Alnylam Pharmaceuticals, Inc.


07/21/16
20160208235 

Detection and removal of misfolded proteins/peptides


The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.
Oxprotect Gmbh


07/21/16
20160208011 

Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same


Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating ccr3, e.g., by modulating eotaxin-1/ccr3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment.
The United States Government As Represented By The Department Of Veterans Affairs


07/21/16
20160208000 

Immunoreceptor modulation for treating cancer and viral infections


A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing cd96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing cd96 activity does not include, or depend upon, killing of cd96-expressing cells in the mammal.
The Council Of The Queensland Institute Of Medical Research


07/21/16
20160206773 

Composition and stopping hemorrhage, infection, and accelerating healing in various types of wound or burns


A composition and a method of applying the composition to a site on or within a body of a mammal. The composition includes a hydrogel matrix that includes at least one polymer cross linked, via ionic or covalent bonding, with both hyaluronic acid and alginic acid.

07/21/16
20160206749 

Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells


Cholesterol moieties are linked to specific ends of double-stranded rna, preferably a small, interfering (si)rna or to a dshybrid. The dshybrid has one strand comprised of dna and one strand comprised of rna.
Marina Biotech, Inc.


07/21/16
20160206723 

Bacterial artificial chromosomes


The invention relates to the use of a bacterial artificial chromosome (bac) for the preparation of a vaccine, wherein the bac comprises an inducible bacterial ori sequence for amplification of the bac to more than 10 copies per bacterial cell. Plus a viral expression cassette comprising a cdna of an attenuated rna virus genome and comprising cis-regulatory elements for transcription of said viral cdna in mammalian cells and for processing of the transcribed rna into infectious viral rna..
Katholieke Universiteit Leuven


07/21/16
20160206711 

Treatment of mammalian physiological reaction of ige antibodies present in said mammal upon contact with the corresponding antigen


A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of ige antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (cnt) derived from clostridia sp.. .

07/21/16
20160206705 

Antiviral activity of gas6 inhibitor


Compositions and methods are provided for treating viral infection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits axl, mer or tyro3 protein activity, for example by inhibition of the binding interaction between axl, mer or tyro3 and its ligand gas6.. .
Ruga Corporation


07/21/16
20160206704 

Method


A method of using a vector comprising a transgene to treat a disease or condition of the eye, the method comprising the steps: (a) administering a solution to a mammalian subject by subretinal injection in an amount effective to at least partially detach the retina to form a subretinal bleb, wherein the solution does not comprise the vector; and (b) administering a medicament composition by subretinal injection into the bleb formed by step (a), wherein the medicament comprises the vector and is injected in an amount effective to treat the disease or condition; wherein the transgene is expressible in cells of the mammalian subject.. .
Isis Innovation Limited


07/21/16
20160206698 

Use of compounds with thrombopoietic activity to promote bone growth and healing


Tpo was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap.
Indiana University Research & Technology Corporation


07/21/16
20160206668 

Production of probiotics by in vitro enrichment of beneficial microorganisms from human or animal microbiota


The present invention is directed to a method of treating a dysbiosis in a mammal, preferably a human, by taking a sample of the micro-organisms that are causative of the dysbiosis, whereafter said sample is enriched in vitro for healthy bacteria, after which the sample is replaced.. .
Nederlandse Organisatie Voor Toegepast-natuurwetenschappelijk Onderzoek Tno


07/21/16
20160206665 

Encapsulated cells for hormone replacement therapy


A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition the composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes.
Wake Forest University Health Sciences


07/21/16
20160206625 

Molybdenum compounds for use in the treatment of cyanide poisoning


The present invention relates to compositions comprising molybdenum compounds, novel molybdenum compounds, kits and methods for their preparation. In particular, the present invention relates to compositions comprising molybdenum compounds for use in the treatment of cyanide poisoning in mammals, in particular humans..
HÁskÓli Íslands


07/21/16
20160206608 

Crizotinib for use in the treatment of cancer


The present invention relates to the use of ros kinase inhibitors for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer mediated by at least one genetically altered ros.
Pfizer Inc.


07/21/16
20160206598 

Therapeutic agent for dyslipidemia


This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states, such as hyper-ldl cholesterolemia, in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, said drug composition comprising the following: (r)-2-[3-[[n-(benzoxazole-2-yl)-n-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of either; and an omega-3 fatty acid or an ester derivative of an ω-3 fatty acid..
Kowa Company, Ltd.


07/21/16
20160206597 

New use


The present invention relates to methods and pharmaceutical compositions for renal protection in a mammal in need thereof, such as a mammal having a disease manifested by atrial enlargement and/or remodeling or suffering from hypertension or heart failure or being prone to suffering from hypertension and/or heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an angiotensin receptor neprilysin inhibitor (arni) or of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi) or with a nepi pro-drug to said mammal.. .

07/21/16
20160206576 

N-acetylcysteine amide (nac amide) in the treatment of diseases and conditions associated with oxidative stress


Methods and compositions comprising n-acetylcysteine amide (nac amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of nac amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione..

07/21/16
20160206558 

Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic


Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“gi”) of a mammal for an extended period of time..
Depomed, Inc.


07/21/16
20160206543 

Synergistic compositions and methods for mitigating skin irritation and enhancing skin barrier function


Methods and compositions are provided for mitigating the irritation of mammalian skin cells, protecting cell viability and/or enhancing cell-cell junction, thus improving skin barrier function. The compositions contain combinations of acetyl hexapeptides and a cosmetically and/or pharmaceutically acceptable carrier.
Gojo Industries, Inc.


07/21/16
20160206479 

Easy removal adhesive article


An elongate adhesive article having a length substantially greater than a width includes a backing layer having an adhesive layer and a single weakened region formed of a removable strip of backing layer that is oriented substantially perpendicular to the article length. The removable strip of backing layer is at least partially defined by a pair of lines of weakness separated by a gap of between about 2 and about 15 mm.
Johnson & Johnson Consumer Inc.


07/21/16
20160206324 

Devices, systems, and methods to precondition, arterialize and/or occlude a mammalian luminal organ


Devices, systems, and methods to precondition, arterialize, and/or occlude a mammalian luminal organ. In an exemplary embodiment of a device for preconditioning, arterializing, and/or occluding a mammalian luminal organ of the present disclosure, the device comprises a frame comprising a plurality of struts, wherein at least one strut of the plurality of struts forms a local general perimeter or boundary of the device, and an expandable occluder coupled to the frame and comprising a membrane or other expandable material that can generally expand and/or unfold as device shifts from a first configuration to a second configuration..
Cvdevices, Llc


07/14/16
20160202241 

Nanofibrous photoclickable hydrogel microarrays


Nanofibrous hydrogel microarray systems that act as facile, high throughput platforms for in vitro drug discovery and investigation and screening of combinatorial effects of physical and biochemical cues on maturation and differentiation of mammalian cells.. .
The Regents Of The University Of Colorado, A Body Corporate






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8228

4241

1 - 1 - 101